Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis... see more

Recent & Breaking News (TSX:EDT)

Spectral Files Final PMA Module for Toraymyxin(TM) With FDA

MarketWire Canada May 30, 2017

Spectral Announces First Quarter Results

MarketWire Canada May 12, 2017

Spectral Expands Distribution of EAA(TM) In the Middle and Far East and in Europe

Marketwired April 26, 2017

Spectral Announces Fourth Quarter and Fiscal 2016 Results

Marketwired March 30, 2017

U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

MarketWire Canada March 7, 2017

Spectral to File Final PMA Module With the FDA for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

MarketWire Canada February 23, 2017

Spectral Voluntarily Delists From OTCQX

MarketWire Canada December 14, 2016

Spectral Announces Appointment of Dr. Masayuki Kaneko to Its Board of Directors

MarketWire Canada December 5, 2016

Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results

MarketWire Canada November 11, 2016

Spectral Announces Clinical Trial Results

MarketWire Canada October 3, 2016

IIROC Trade Resumption - EDT

Canada NewsWire September 20, 2016

Spectral Responds to Recent Trading Activity

MarketWire Canada September 20, 2016

IIROC Trading Halt - EDT

Canada NewsWire September 20, 2016

Spectral Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016

MarketWire Canada September 7, 2016

Spectral Unaware of Any Material Change

MarketWire Canada August 19, 2016

Spectral on Track With Regulatory Pathway for Novel Septic Shock Treatment

MarketWire Canada August 18, 2016

H2O Innovation: Clearlogx(R) Patented Technology Improves Membrane Plant Performance and Reduces OPEX at Brazos Regional Public Utility Agency (Texas)

MarketWire Canada August 18, 2016

Spectral Announces Second Quarter Results

MarketWire Canada August 12, 2016

Spectral Announces Normal Course Issuer Bid

MarketWire Canada July 4, 2016

FDA Accepts Spectral's Expanded Access Protocol for Toraymyxin(TM)

MarketWire Canada June 27, 2016